mHSPC
Metastatic hormone-sensitive prostate cancer
Advertisement
Adding niraparib to abiraterone and prednisone prolongs rPFS in patients with mCSPC harboring HRR gene alterations.
Drs. Ong and Roy detail a multinational real-world analysis of the IRONMAN registry on the significance of PSA>0.2.
Drs. Swami and Ciuro discuss adoption of treatment intensification, barriers to guideline-concordant care, and more in mHSPC.
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
Researchers evaluated SBRT plus short-term hormonal therapy in oligometastatic HSPC, examining the tolerability and efficacy.
Researchers evaluated the addition of zoledronic acid to the standard treatment of enzalutamide and ADT.
Drs. Swami and Ciuro discuss real-world data that indicates a shift in mHSPC treated with intensified therapy since 2023.
Dr. Shore highlights post hoc analyses of ultra-low PSA responses and their correlation with outcomes in the ARANOTE study.
A recent study evaluated the impact of early withdrawal of upfront ARSIs on clinical outcomes in patients with mCSPC.
Apalutamide can boost rPFS and OS in patients with mHSPC when diagnosed via conventional imaging.
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Dr. Ciuro discusses key factors to consider when choosing between doublet and triplet therapy for mHSPC.
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
Patients with mHSPC who are younger, have a high BMI, or have low-volume disease may benefit more from treatment with ARPIs.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.